KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process (2017 - 2020)

Amneal Pharmaceuticals has reported Work In Process over the past 4 years, most recently at $53.1 million for Q1 2020.

  • For Q1 2020, Work In Process changed N/A year-over-year to $53.1 million; the TTM value through Mar 2020 reached $53.1 million, changed N/A, while the annual FY2019 figure was $58.2 million, 7.45% up from the prior year.
  • Work In Process for Q1 2020 was $53.1 million at Amneal Pharmaceuticals, down from $58.2 million in the prior quarter.
  • Over five years, Work In Process peaked at $59.2 million in Q2 2018 and troughed at $38.1 million in Q4 2017.
  • A 4-year average of $50.4 million and a median of $52.1 million in 2018 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: soared 41.96% in 2018 and later plummeted 35.13% in 2019.
  • Year by year, Work In Process stood at $38.1 million in 2017, then soared by 41.96% to $54.2 million in 2018, then grew by 7.45% to $58.2 million in 2019, then dropped by 8.79% to $53.1 million in 2020.
  • Business Quant data shows Work In Process for AMRX at $53.1 million in Q1 2020, $58.2 million in Q4 2019, and $50.8 million in Q3 2019.